BDKRB1 and multiple sclerosis: B1R blockade has been shown to dramatically reduce inflammatory processes and edema formation not only in ARDS but also in models of acute ischemic stroke (Austinat et al., 2009), traumatic brain injury (Raslan et al., 2010) and multiple sclerosis (Göbel et al., 2011).